Connect Biopharma Holdings Limited (CNTB)
After hours:
| Previous close | 1.6400 |
| Open | 1.7900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.5300 - 1.7900 |
| 52-week range | 0.5350 - 2.8400 |
| Volume | |
| Avg. volume | 116,544 |
| Market cap | 88.165M |
| Beta (5Y monthly) | -0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0800 |
| Earnings date | 16 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.13 |
GlobeNewswireConnect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that the Board of Directors (Board), including all of the independent directors of the Board, granted to Barry Quart
- GlobeNewswire
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-
Simply Wall St.Connect Biopharma Holdings Limited's (NASDAQ:CNTB) top owners are private equity firms with 39% stake, while 22% is held by insiders
Key Insights Significant control over Connect Biopharma Holdings by private equity firms implies that the general...
